Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Pre to Postoperative Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 5
- Registration Number
- NCT02683161
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
UW-CTRI Triple Medication Smoking Cessation Study
- Conditions
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 36
- Registration Number
- NCT02681510
- Locations
- 🇺🇸
UW CTRI, Madison, Wisconsin, United States
What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- University of Bristol
- Target Recruit Count
- 180000
- Registration Number
- NCT02681848
Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 242
- Registration Number
- NCT02634281
- Locations
- 🇮🇱
Shaare Zedek Medical center, Jerusalem, Israel
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT02582008
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
A Smoking Cessation Intervention for Yale Dining Employees
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 25
- Registration Number
- NCT02562521
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)
- Conditions
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Duke University
- Target Recruit Count
- 125
- Registration Number
- NCT02551692
- Locations
- 🇺🇸
Duke Medical Center, Durham, North Carolina, United States
Effects of Varenicline in Heavy Drinking Smokers
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT02488889
- Locations
- 🇺🇸
UCLA Addictions Laboratory, Los Angeles, California, United States
Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 22
- Registration Number
- NCT02473562
- Locations
- 🇳🇱
VU university medical center, Amsterdam, Netherlands
🇳🇱Academic Medical Center, Amsterdam, Netherlands
Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 184
- Registration Number
- NCT02460900
- Locations
- 🇺🇸
University of Maryland Medical Center, Midtown Campus, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.